Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lyra Therapeutics (LYRA) Interest & Investment Income (2021 - 2025)

Historic Interest & Investment Income for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to $256000.0.

  • Lyra Therapeutics' Interest & Investment Income fell 5555.56% to $256000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 6370.95%. This contributed to the annual value of $3.0 million for FY2024, which is 3438.54% down from last year.
  • Lyra Therapeutics' Interest & Investment Income amounted to $256000.0 in Q3 2025, which was down 5555.56% from $410000.0 recorded in Q2 2025.
  • Over the past 5 years, Lyra Therapeutics' Interest & Investment Income peaked at $1.3 million during Q4 2023, and registered a low of $14000.0 during Q1 2022.
  • For the 5-year period, Lyra Therapeutics' Interest & Investment Income averaged around $503052.6, with its median value being $410000.0 (2025).
  • Per our database at Business Quant, Lyra Therapeutics' Interest & Investment Income skyrocketed by 755714.29% in 2023 and then plummeted by 7255.99% in 2025.
  • Lyra Therapeutics' Interest & Investment Income (Quarter) stood at $21000.0 in 2021, then surged by 4342.86% to $933000.0 in 2022, then soared by 43.41% to $1.3 million in 2023, then crashed by 67.49% to $435000.0 in 2024, then crashed by 41.15% to $256000.0 in 2025.
  • Its last three reported values are $256000.0 in Q3 2025, $410000.0 for Q2 2025, and $298000.0 during Q1 2025.